Treatment options for mCRPC following androgen deprivation and taxane therapy are limited. Preclinical and limited clinical data suggest efficacy of PARP inhibition in HRR-deficient PCa.
TRITON2 (NCT02952534; target enrolment, 157 pts) is evaluating rucaparib 600 mg BID in pts with a deleterious germline or somatic alteration in
At the 6 Mar 2018 data cutoff date, 52 pts were treated with rucaparib. Median duration of follow-up was 3.7 mo (range, 1.0–12.6). Twenty-six pts (50%) had a
Rucaparib has encouraging antitumour activity in mCRPC pts with a deleterious alteration in
Clovis Oncology, Inc.
Clovis Oncology, Inc.
Writing and editorial support, funded by Clovis Oncology, Inc. (Boulder, CO, USA) was provided by Nathan Yardley, PhD, and Shannon Davis of Ashfield Healthcare Communications (Middletown, CT, USA).
W. Abida: Consulting, Advisory role: Clovis Oncology; Honoraria: Caret Healthcare; Research funding: AstraZeneca, Zenith Epigenetics. N.J. Vogelzang: Consulting, Advisory role: Caris, Sanofi Aventis, Bayer, Pfizer, Janssen, AstraZeneca, Astellas; Stock options owner: Caris; Editor: Up-To-Date. R.J. Amato: Consulting, Advisory role, Speaker bureaus: Jansen, Astellas/Pfizer (Medivation), Novartis. A. Hussain: Consulting, Advisory role: Bayer, Bristol-Myers Squibb, AstraZeneca. A. Patnaik: Consulting, Advisory role: Janssen; Research funding: Bristol-Myers Squibb, GlaxoSmithKline. D. Petrylak: Consulting, Advisory role: Bayer, Bellicum Pharmaceuticals, Dendreon, Johnson & Johnson, Exelixis, Ferring, Millenium, Medivation, Pfizer, Roche, Sanofi and Tyme Pharmaceuticals; Expert testimony: Celgene, Sanofi; Research funding: Oncogenex, Progenics, Johnson & Johnson, Dendreon, Sanofi, Endocyte, Genentech, Merck, Astellas Medivation, Novartis, Agensys, AstraZeneca, Bayer, Lilly, Innocrin Pharma, MedImmune, Millineum, Pfizer, Roche, Sotio; Stock owner, Other ownership interests: Bellicum Pharmaceuticals and Tyme, Inc. C.J. Ryan: Consulting, Advisory role: Bayer, Millennium; Honoraria: Janssen Oncology, Astellas Pharma; Research funding: BIND Biosciences, Karyopharm Therapeutics, Novartis. J. Zhang: Consulting, Advisory role, Speaker’s bureaus: AstraZeneca, Sanofi; Research funding: AstraZeneca, Astellas Pharma, Bayer. A.D. Simmons, D. Despain, M. Collins, T. Golsorskhi: Employee, Stock owner, Stock option owner: Clovis Oncology. H.I. Scher: Consulting, Advisory role: AstraZeneca, Astellas Pharma, Bristol-Myers Squibb, Celgene, Endocyte, Exelixis, Endo Pharmaceuticals, Ferring, Foundation Medicine, Genentech, Janssen, OncologySTAT, Palmetto GBA, Pfizer, Sanofi, Takeda, Ventana Medical Systems, BIRB-Copernicus Group, Medivation; Speaker’s bureau: WebMD; Travel, accommodation: Exelixis, Janssen, Sanofi, Endocyte, AstraZeneca, Genentech, Bristol-Myers Squibb, Celgene, Pfizer, Takeda, Ferring, WIRB-Copernicus Group, and Astellas Pharma; Honoraria: Chugai Pharma; Research funding: BIND Biosciences, Exelixis, Janssen, Medivation, Janssen Diagnostics. S. Chowdhury: Consulting, Advisory role, Speaker’s bureaus: Clovis Oncology, Sanofi, Pfizer, Astellas Pharma, Janssen; Honoraria: GlaxoSmithKline, Novartis; Research funding: Sanofi, Johnson & Johnson. All other authors have declared no conflicts of interest.